Design, Synthesis and Biological Evaluation of Trypanosoma brucei Trypanothione Synthetase Inhibitors

被引:38
作者
Spinks, Daniel [1 ]
Torrie, Leah S. [1 ]
Thompson, Stephen [1 ]
Harrison, Justin R. [1 ]
Frearson, Julie A. [1 ]
Read, Kevin D. [1 ]
Fairlamb, Alan H. [1 ]
Wyatt, Paul G. [1 ]
Gilbert, Ian H. [1 ]
机构
[1] Univ Dundee, Coll Life Sci, Drug Discovery Unit, Div Biol Chem & Drug Discovery, Dundee DD1 5EH, Scotland
基金
英国惠康基金;
关键词
antiprotozoal agents; drug design; Trypanosoma brucei; trypanothione synthetase; HUMAN AFRICAN TRYPANOSOMIASIS; DRUG TARGET; METABOLISM; REDUCTASE; BIOSYNTHESIS; LEISHMANIA; LEAD;
D O I
10.1002/cmdc.201100420
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Trypanothione synthetase (TryS) is essential for the survival of the protozoan parasite Trypanosoma brucei, which causes human African trypanosomiasis. It is one of only a handful of chemically validated targets for T. brucei in vivo. To identify novel inhibitors of TbTryS we screened our in-house diverse compound library that contains 62?000 compounds. This resulted in the identification of six novel hit series of TbTryS inhibitors. Herein we describe the SAR exploration of these hit series, which gave rise to one common series with potency against the enzyme target. Cellular studies on these inhibitors confirmed on-target activity, and the compounds have proven to be very useful tools for further study of the trypanothione pathway in kinetoplastids.
引用
收藏
页码:95 / 106
页数:12
相关论文
共 29 条
[11]   TRYPANOTHIONE - A NOVEL BIS(GLUTATHIONYL)SPERMIDINE COFACTOR FOR GLUTATHIONE-REDUCTASE IN TRYPANOSOMATIDS [J].
FAIRLAMB, AH ;
BLACKBURN, P ;
ULRICH, P ;
CHAIT, BT ;
CERAMI, A .
SCIENCE, 1985, 227 (4693) :1485-1487
[12]   Chemotherapy of human African trypanosomiasis: current and future prospects [J].
Fairlamb, AH .
TRENDS IN PARASITOLOGY, 2003, 19 (11) :488-494
[13]   Target assessment for antiparasitic drug discovery [J].
Frearson, Julie A. ;
Wyatt, Paul G. ;
Gilbert, Ian H. ;
Fairlamb, Alan H. .
TRENDS IN PARASITOLOGY, 2007, 23 (12) :589-595
[14]  
FUJIMURA Y, 1984, CHEM PHARM BULL, V32, P3252
[15]   Leishmania trypanothione synthetase-amidase structure reveals a basis for regulation of conflicting synthetic and hydrolytic activities [J].
Fyfe, Paul K. ;
Oza, Sandra L. ;
Fairlamb, Alan H. ;
Hunter, William N. .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2008, 283 (25) :17672-17680
[16]  
Goldfarb D. S., 2009, U S Pat Appl. Publ., Patent No. [US 20090163545, Al 20090625, 20090163545, US 20090163545]
[17]   Ligand efficiency: a useful metric for lead selection [J].
Hopkins, AL ;
Groom, CR ;
Alex, A .
DRUG DISCOVERY TODAY, 2004, 9 (10) :430-431
[18]   Identification of a κ-opioid agonist as a potent and selective lead for drug development against human African trypanosomiasis [J].
Jones, Deuan C. ;
Hallyburton, Irene ;
Stojanovski, Laste ;
Read, Kevin D. ;
Frearson, Julie A. ;
Fairlamb, Alan H. .
BIOCHEMICAL PHARMACOLOGY, 2010, 80 (10) :1478-1486
[19]   The parasite-specific trypanothione metabolism of trypanosoma and leishmania [J].
Krauth-Siegel, RL ;
Meiering, SK ;
Schmidt, H .
BIOLOGICAL CHEMISTRY, 2003, 384 (04) :539-549
[20]   Trypanosomes lacking trypanothione reductase are avirulent and show increased sensitivity to oxidative stress [J].
Krieger, S ;
Schwarz, W ;
Ariyanayagam, MR ;
Fairlamb, AH ;
Krauth-Siegel, RL ;
Clayton, C .
MOLECULAR MICROBIOLOGY, 2000, 35 (03) :542-552